Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 64, Issue 8, 819-826
Copyright © 2007 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arnold, T. M.
Right arrow Articles by Messmer, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arnold, T. M.
Right arrow Articles by Messmer, K. J.

Therapy Update

Polymyxin antibiotics for gram-negative infections

Tamra M. Arnold, Graeme N. Forrest and Karen J. Messmer

TAMRAM. ARNOLD, PHARM.D., BCPS, is Clinical Pharmacy Specialist, Richard L. Roudebush Veterans Affairs Medical Center (VAMC), Indianapolis, IN. GRAEMEN. FORREST, M.D., M.B.B.S., is Assistant Professor, School of Medicine, University of Maryland, Baltimore, and Assistant Director, Infectious Diseases, Greenbaum Cancer Center, Baltimore. KARENJ. MESSMER, PHARM.D., is Clinical Pharmacy Specialist, Richard L. Roudebush VAMC.

Address correspondence to Dr. Arnold at the Richard L. Roudebush Veterans Affairs Medical Center, 1481 West 10th Street, Indianapolis, IN 46202 (tamra.arnold{at}va.gov).


Purpose. The role of polymyxin antibiotics in the treatment of multidrug-resistant gram-negative infections is reviewed.

Summary. Antimicrobial resistance is an increasing problem across hospitals worldwide, especially in intensive care settings, where nosocomial infections are 5–10 times more likely to occur than on the general wards. The polymyxins, a group of basic polypeptide antibiotics, were first isolated from Bacillus species in the late 1940s and appear to have a surface detergent effect, making them active against most gram-negative organisms. Early clinical reports suggested a high rate of toxicity associated with the polymyxins, specifically nephrotoxicity (20%) and neurotoxicity (7%); thus the polymyxins had largely fallen out of favor. However, recent studies have suggested that the toxicities associated with the polymyxins may be less severe and less frequent than earlier reports. The emergence of multidrug-resistant gram-negative organisms has led to a reemergence in the use of this antibiotic class. Various clinical trials that evaluated the polymyxins for the treatment of multidrug-resistant gram-negative organisms found that these antibiotics have acceptable effectiveness and may be used if necessary.

Conclusion. The polymyxins have become a last resort for the treatment of infections caused by multidrug-resistant gram-negative organisms. Recent studies have suggested that the frequency of polymyxin-associated nephrotoxicity and neurotoxicity may not be as high as was once thought. The polymyxins seem to be effective in treating various infections caused by multidrug-resistant gram-negative organisms but should not be used as first-line therapy until more is known about this class of antibiotics.

Index terms: Antibiotics; Drug use; Gram-negative bacterial infections; Hospitals; Polymyxin; Rational therapy; Resistance; Toxicity

 



This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
G. N. Forrest and K. Tamura
Rifampin Combination Therapy for Nonmycobacterial Infections
Clin. Microbiol. Rev., January 1, 2010; 23(1): 14 - 34.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Barrow and D. H. Kwon
Alterations in Two-Component Regulatory Systems of phoPQ and pmrAB Are Associated with Polymyxin B Resistance in Clinical Isolates of Pseudomonas aeruginosa
Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5150 - 5154.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
T. Mogi, Y. Murase, M. Mori, K. Shiomi, S. Omura, M. P. Paranagama, and K. Kita
Polymyxin B Identified as an Inhibitor of Alternative NADH Dehydrogenase and Malate: Quinone Oxidoreductase from the Gram-positive Bacterium Mycobacterium smegmatis
J. Biochem., October 1, 2009; 146(4): 491 - 499.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
L. Weinstein, T.-L. Doan, and M. A. Smith
Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports
Am. J. Health Syst. Pharm., February 15, 2009; 66(4): 345 - 347.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Health-System Pharmacists.
Advertisement